DR. VERGHESE MATHEW'S WNICER APPOINTMENT
Mr. John Brooks, CEO of the Worldwide Network for Innovation in Clinical Education and Research (WNICER) is pleased to announce that Dr. Verghese Mathew will assume the role of Director of the Cardiovascular Investigator Program at the WNICER effective Monday, December 16, 2019.
Dr. Mathew is a Professor of Medicine at Loyola University Chicago Stritch School of Medicine. He has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016, holding a number of leadership positions in the cardiac and vascular arenas, with joint appointments in the departments of medicine, cardiology, and radiology; he was recruited to Loyola University Medical Center in 2016 to lead the division of cardiology.
Dr. Mathew has done extensive work in the field of interventional cardiology including complex CAD, peripheral arterial interventions, and TAVR- with both basic and translational research programs. He has been an investigator in many trials that have evaluated and led to the approval of currently utilized technologies, such as coronary stents/drug eluting stents and transcatheter aortic valve replacement (TAVR); as well as phase II-IV pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions. He has published extensively in the field of interventional cardiology.
Dr. Mathew has a keen interest in integrated models of care, focusing on the appropriate application of advanced cardiovascular therapies to complex patient subsets. He continues to be an invited speaker at many national and international cardiovascular scientific conferences.
Dr. Mathew is board certified in interventional cardiology and cardiovascular diseases. He is a Fellow of the American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Interventions.
WNICER chosen to support the MINICOR Initiative
The Multi-modal International Cardiomyopathy Outcome Registry (MINICOR) to be supported by the WNICER organization.
After several years of collaborative discussions across the imaging, heart failure and electrophysiology communities, a global multi-institutional initiative called MINICOR is set to be launched over the next 12-months. As the largest prospective data collection initiative in cardiovascular care to date, it is planned to bridge over 40 institutions and 10 vendors to collectively explore data-driven approaches to the management of patients with heart failure and those at risk for arrhythmia.
Uniquely, MINICOR is equally represented across the fields of cardiovascular imaging, heart failure and electrophysiology. With international leaders from each respective field, the initiative will enable unprecedented collaboration to re-define the complete care pathway of patients with cardiomyopathy from initial presentation through to diagnostic testing, risk prediction modelling and care implementation.
Core to the vision of MINICOR is the engagement of patients as partners in healthcare innovation. Patients at participating institutions will be enabled with transparent cloud-based control over the use of their anonymized data and will be provided regular updates regarding how their data has benefited researchers and led to technology development.
Technology development and implementation
Uniquely managed through WNICER, commercial partners investing in the MINICOR initiative will be engaged to ensure clinical translation of data-driven tools to improve cardiovascular care "at scale". As innovation reaches the clinical arena, patients contributing to its development will be informed and participate in the management of royalties generated by its success.